You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 23, 2025

Patent: 7,572,776


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,572,776
Title:N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
Abstract: The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system.
Inventor(s): Yu; Ruey J. (Chalfont, PA), Van Scott; Eugene J. (Abington, PA)
Application Number:12/194,203
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Patent Landscape: A Comprehensive Analysis of US Patent 7,572,776

Introduction

Patents are a cornerstone of innovation, providing inventors and companies with exclusive rights to their inventions. The United States Patent and Trademark Office (USPTO) is responsible for granting these rights, but the process is complex and influenced by various factors. This article will delve into the specifics of US Patent 7,572,776, examining its claims, the broader patent landscape, and the implications of recent changes in patent law.

Background on US Patent 7,572,776

While the specific details of US Patent 7,572,776 are not provided in the sources, we can infer general insights from similar patents and the patent process.

Patent Claims and Scope

Patent claims define the scope of the invention and are crucial for determining what is protected. Claims must be novel, non-obvious, and directed to patent-eligible subject matter[2].

  • Novelty Requirement: The claimed invention must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date[2].
  • Nonobviousness Requirement: The invention must be significantly different from existing technology and not obvious to a person of ordinary skill in the relevant field[2].

Continuation Procedures

Patent applications often involve continuation procedures, which can significantly impact the patent landscape. Continuations allow applicants to file additional applications based on the original (progenitor) application, potentially leading to multiple patents from a single initial filing[1].

  • Requests for Continued Examination (RCEs): These are common non-serialized continuations that allow applicants to continue the examination process without abandoning the progenitor application[1].
  • Serialized Continuations: These include continuation-in-part (CIP) and divisional applications, which can introduce new subject matter or separate distinct inventions, respectively[1].

The Patent Landscape in the United States

Patent Trial and Appeal Board (PTAB)

The Leahy-Smith America Invents Act (AIA) of 2011 significantly altered the patent landscape by establishing the PTAB. This board hears administrative challenges to patent validity, including inter partes review (IPR) and post-grant review (PGR)[2].

  • IPR and PGR: These procedures provide a faster and less expensive way to challenge patent validity compared to federal court litigation. They use a lower standard of proof (preponderance of the evidence) and are typically decided within one year[2].

Patent Assertion Entities (PAEs)

PAEs, often referred to as "patent trolls," play a significant role in the patent landscape. They acquire and assert patents without manufacturing or selling the patented products.

  • Portfolio PAEs: These entities negotiate licenses for large portfolios of patents, often without litigation. They generate significant revenue from these licenses[3].
  • Litigation PAEs: These entities primarily assert patents through litigation, with a high percentage of licenses following patent infringement suits[3].

Challenges and Criticisms

Patent Quality and Litigation

One of the primary concerns is the quality of patents issued by the USPTO. Poor-quality patents can fuel litigation and hinder innovation. The AIA aimed to improve patent quality by providing more efficient means to adjudicate patent validity issues through PTAB[2].

Transparency and Abuse

Transparency issues, particularly with multi-affiliate structures of PAEs, can complicate the patent landscape. These structures can make it difficult to track the true owners of patents and their assertion activities[3].

Impact of Recent Changes

Subject Matter Eligibility

The USPTO has issued guidelines to determine whether patent applications seek to claim ineligible subject matter, such as laws of nature, natural phenomena, or abstract ideas. The Alice/Mayo test is used to assess whether the claims have an "inventive concept" that transforms the ineligible subject matter into a patent-eligible application[2].

International Perspectives

Regulations in other jurisdictions, such as the European Commission's proposal for SEP regulation, highlight the global complexities of patent law. For example, the non-binding FRAND determination process can lead to delays and unfair advantages for implementers[5].

Key Takeaways

  • Patent Claims: The scope and validity of patent claims are critical and must meet novelty, nonobviousness, and subject matter eligibility requirements.
  • Continuation Procedures: These can significantly extend the life and scope of a patent application.
  • PTAB and Administrative Challenges: The PTAB provides a faster and less expensive way to challenge patent validity compared to federal court litigation.
  • PAEs: These entities can impact the patent landscape through licensing and litigation, with different business models affecting revenue and litigation strategies.
  • Transparency and Quality: Ensuring transparency and improving patent quality are ongoing challenges in the patent system.

FAQs

What is the role of the Patent Trial and Appeal Board (PTAB) in the US patent system?

The PTAB is a tribunal within the USPTO that hears administrative challenges to the validity of patents, including inter partes review (IPR) and post-grant review (PGR), providing a faster and less expensive alternative to federal court litigation[2].

How do continuation procedures affect patent applications?

Continuation procedures allow applicants to file additional applications based on the original application, potentially leading to multiple patents and extending the examination process. This includes RCEs, CIPs, and divisional applications[1].

What are the differences between Portfolio PAEs and Litigation PAEs?

Portfolio PAEs negotiate licenses for large portfolios of patents without often resorting to litigation, generating significant revenue. Litigation PAEs primarily assert patents through litigation, with most licenses following patent infringement suits[3].

What is the significance of the Alice/Mayo test in patent law?

The Alice/Mayo test is used to determine whether patent claims directed to ineligible subject matter (like abstract ideas) have an "inventive concept" that makes them patent-eligible. This test ensures that patents are granted only for inventions that significantly advance the field[2].

How do international regulations impact the US patent landscape?

International regulations, such as the European Commission's SEP proposal, can influence global patent strategies and highlight the need for consistent and fair patent practices across jurisdictions[5].

Sources

  1. Carley, M., & Hegde, D. (n.d.). What Is the Probability of Receiving a US Patent?. Emory Law Journal.
  2. Congressional Research Service. (2024). The Patent Trial and Appeal Board and Inter Partes Review. CRS Reports.
  3. Federal Trade Commission. (n.d.). Patent Assertion Entity Activity: An FTC Study.
  4. Kowalski, M. M., Young, J. L., & Moore, K. A. (2011). METHOD OF TREATING POSTSURGICAL ACUTE PAIN. US Patent 7,884,095 B2.
  5. Kluwer IP Law. (2024). A Critical Analysis of the EC Proposal for SEP Regulation. Patent Blog.

More… ↓

⤷  Try for Free

Details for Patent 7,572,776

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Ferring Pharmaceuticals Inc. ACTHREL corticorelin ovine triflutate For Injection 020162 May 23, 1996 ⤷  Try for Free 2026-01-10
Bayer Healthcare Pharmaceuticals Inc. TRASYLOL aprotinin Injection 020304 December 29, 1993 ⤷  Try for Free 2026-01-10
Ony Biotech Inc. INFASURF calfactant Suspension 020521 July 01, 1998 ⤷  Try for Free 2026-01-10
Ony Biotech Inc. INFASURF calfactant Suspension 020521 December 12, 2002 ⤷  Try for Free 2026-01-10
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.